Case Presentation

A 73 year-old man, current smoker of 50 pack-years, a history of chronic obstructive pulmonary disease (COPD) on home oxygen, and an ischemic cardiomyopathy presented to the emergency department (ED) with shortness of breath. He noted 1 week of progressive dyspnea on exertion and increasing cough with purulent sputum. He denied fever, chills, hemoptysis, orthopnea, paroxysmal nocturnal dyspnea and leg edema. He has been using inhaled bronchodilators several times daily and had increased the flow rate of his supplemental oxygen to 4 liters per minute without notable improvement. On the morning of admission, he had dyspnea, even at rest, and called EMS. On presentation, he was afebrile, tachycardic to 110 beats per minute and hypertensive to 178/90 mmHg; he had a respiratory rate of 36 breaths per minute and an oxygen saturation of 85% on 4 liters per minute of supplemental oxygen via nasal cannula. An ABG drawn while on oxygen revealed: pH 7.24, pCO2 60 mmHg, PO2 55 mmHg. On exam, he was awake, in mild distress, using accessory muscles of inspiration and exhalation. The remainder of his exam was notable for tachycardia, diffuse end-expiratory wheezes bilaterally, and an absence of rales. Chest radiograph demonstrated hyperinflation without focal opacity.

Question

What is the immediate approach to this patient with acute hypercarbic respiratory failure?

Answer

Non-invasive positive-pressure ventilation (NIPPV) is the preferred method of ventilatory support in patients with acute respiratory failure secondary to an acute exacerbation of COPD (AECOPD). This patient was placed on bilevel NIPPV with an inspiratory pressure of 12 cm of water and an expiratory pressure of 5 cm of water with an inspired fraction of oxygen of 0.5 via an oronasal mask interface. His oxygen saturation was maintained between 88 and 92%. He was given 500 mg of intravenous azithromycin and 60 mg of intravenous methylprednisolone. Within hours, his respiratory rate had decreased to 22 and he appeared comfortable with improvement in his arterial blood gas.

Principles of Management

Diagnosis and Impact of COPD Exacerbations

The natural history of COPD is punctuated by periods of acute exacerbation, during which patients experience increased symptoms and utilize more healthcare resources. Common symptoms of AECOPD include increased sputum production, cough and dyspnea as a result of increased airway inflammation, mucous plugging and gas trapping [1, 2]. Exacerbations of COPD are associated with a mortality of 10% in the hospital, 43% at 1 year and 50% in the subsequent 5 years [3–5]. Exacerbations themselves are associated with a step-wise decline in lung function and deteriorating quality of life [6]. The most commonly identified triggers for AECOPD are respiratory viruses, particularly rhinovirus, as well as bacterial pathogens and environmental exposures.

NIPPV

NIPPV is indicated in the setting of acute respiratory failure secondary to COPD exacerbation [7, 8]. The goal of NIPPV in this setting is to reduce work of breathing, improve ventilation, correct hypercarbia and prevent intubation. NIPPV avoids...
many of the risks of invasive ventilation (via an endotracheal tube), including the risk of aspiration, hypotension or trauma during laryngoscopy and placement of the endotracheal tube. In addition, NIPPV preserves airway defenses, which may reduce the risk of ventilator-associated pneumonia and usually does not require sedation or physical restraints. The target oxygen saturation in the setting of a COPD exacerbation is 88–92%, which has been associated with lower mortality compared to non-titrated supplemental oxygen [9].

NIPPV reduces in-hospital mortality in COPD exacerbations in addition to reducing the need for intubation, and hospital length of stay [8, 10]. It has also been shown to reduce respiratory rate and improve respiratory acidosis [11].

Typical settings for NIPPV in COPD exacerbation are bilevel positive pressure support, with an inspiratory pressure set at 8–12 cm H₂O and an expiratory pressure set at 3–5 cm H₂O. Oronasal mask (covering the mouth and nose) interface is generally used due to known benefits in physiologic parameters and wide availability. If not tolerated, a nasal mask or nasal cushions may be more comfortable, with the caveat that they generally have larger air leaks [12, 13]. Newer interfaces including helmet devices may have added benefit, including patient comfort and the ability to drink while receiving positive pressure ventilation, but are not widely used at this time [14].

Indications and absolute contraindications to NIPPV are listed below. Encephalopathy due to hypercapnic respiratory failure is not a contraindication, but requires the frequent monitoring and follow up of the patient to ensure improvement in mental status and respiratory acidosis in the first hours [15].

“NIPPV failure” is better described as the progression or lack of improvement of respiratory failure despite NIPPV, often leading to invasive mechanical ventilation (IMV) [16]. Approximately 30% of patients with AECOPD treated with NIPPV fall into this category [17]. NIPPV failure is associated with a high mortality. Reported mortality ranges from 13.5% in the ICU to 60.2% and is higher than the mortality of those initially placed on IMV [17, 18].

Bronchodilators

Inhaled bronchodilators are the mainstay of treatment for COPD exacerbations. Short acting beta-agonists (e.g., albuterol) have proven reliable and quick-acting bronchodilators. No difference has been found in efficacy between short-acting beta-agonists and anticholinergics delivered via nebulizer or metered-dose inhaler (MDI) [19], although nebulizer may be preferred if the patient is in respiratory failure and unable to generate the negative inspiratory force required for optimal MDI medication delivery. Nair et al. found no difference in maximal bronchodilatory response between 2.5 mg/3 mL and 5 mg/3 mL of nebulized albuterol in COPD exacerbations [20].

Short-acting inhaled anticholinergics (e.g., ipratropium bromide) are often used alongside inhaled beta-agonist therapy [7]. Data are mixed whether the combination of anticholinergic and beta-agonists produce bronchodilation in excess of either alone [21, 22].

Neither intravenous methylxanthines nor beta-agonists are recommended for the treatment of COPD exacerbation.

Glucocorticoids

Systemic glucocorticoids should be given to all patients admitted to the hospital for AECOPD. This therapy improves lung function, reduces rates of treatment failure, improves symptoms and decreases length of stay [23, 24]. One systematic review established that ten patients would need to be treated with systemic corticosteroids to prevent one treatment failure [25]. Intravenous corticosteroids offer no advantage over oral therapy, unless the patient cannot tolerate oral medication [26, 27]. Oral steroids should be stopped after 5 days if the patient has improved clinically. In a single randomized-controlled trial, a five-day course of oral prednisone in AECOPD was shown to be non-inferior to a 14-day course [28].

The ideal dose of corticosteroids in COPD exacerbations is unknown. The GOLD guidelines recommend the dose equivalent of 40 mg of prednisone once daily [7]. Published dosing regimens range from 40 mg of prednisone once daily to 125 mg of methylprednisolone up to four times a day [7, 27, 29]. Systemic steroids, especially at higher doses, have been associated with hyperglycemia [30].

Antibiotics

Although not all COPD exacerbations are due to bacterial pathogens, antibiotics are recommended for all patients with moderate to severe exacerbations, including all patients requiring hospitalization [7]. Antibiotics have been shown to reduce treatment failure in severe exacerbations [31].

Several attempts have been made to define subgroups who may benefit from antibiotics: for example, those with purulent sputum, elevated c-reactive protein (CRP) or procalcitonin. Sputum purulence may be related to bacterial infection, but a clinical benefit from antibiotics has not been established prospectively in this group [32, 33]. Clark et al. showed that an elevated CRP did not reliably distinguish between viral and bacterial infections so is unhelpful in guiding the decision to use antibiotics [34]. Procalcitonin is a promising biomarker, which may help distinguish bacterial and viral infections [35]. Procalcitonin-guided antibiotic
use was associated with similar outcomes but less antibiotic exposure in AECOPD [35]. However, more recent data including patients with either pneumonia or AECOPD failed to replicate this finding [36].

The antibiotic choice for COPD exacerbations should reflect local antibiograms and resistance patterns. Typical duration is 5 days [7], which has similar treatment success to 7 and 10 day courses [37].

**Smoking Cessation**

Although not a treatment for the acute exacerbation, smoking cessation should be addressed in patients who smoke cigarettes and present to a healthcare setting with acute symptoms. Smoking cessation can reduce the frequency of COPD exacerbations by one third [5]. Several effective therapies are available which may promote sustained abstinence from smoking, although a combination of pharmacotherapy with behavioral modifications have the most robust evidence [38].

**Evidence Contour**

**Extracorporeal Carbon Dioxide Removal**

Extracorporeal carbon dioxide removal (ECCO2R) refers to the removal of carbon dioxide (CO₂) from the blood via an extracorporeal gas exchanger. This process, initially explored for the acute respiratory distress syndrome (ARDS), can be part of conventional venovenous (VV) extracorporeal membrane oxygenation (ECMO) or arteriovenous (AV) ECMO [39]. However, more recently, lower flow circuits of only 0.3–1 L/min have been proposed for the purposes of CO₂ removal, particularly in AECOPD to supplement NIPPV and prevent the need for endotracheal intubation [39, 40]. One retrospective analysis compared 21 patients with AECOPD who did not improve on NIPPV and were subsequently intubated with 21 patients treated with a pumpless extracorporeal lung-assist device (PECLA). No difference was noted in ICU or hospital stay, though those treated with PECLA had reduction in PCO₂, improvement in pH, and required no sedation, allowing them to eat, exercise and communicate [41].

Others have evaluated ECCO2R as a tool to facilitate extubation in patients with AECOPD with some success, though in very small numbers: \( n = 5 \) and \( n = 20 \), respectively [42, 43]. Other small studies have been published with similar benefits, but reported significant bleeding complications [44, 45]. A recent metaanalysis concluded that ECCO2R for AECOPD is still experimental, noting both potential benefit, but also serious risk for complications [46]. No prospective randomized trials on the subject have been published, though several are ongoing [40].

**AECOPD and Thromboembolic Disease**

There is a high prevalence of pulmonary embolism (PE) in the setting of unexplained AECOPD, ranging from 16–25% [47–49]. A recent systematic review including 880 patients demonstrated a prevalence of 16.1%, with the majority of the clots located in proximal rather than subsegmental arteries [49]. In this analysis, patients with PE and AECOPD had longer hospital stays and higher mortality. The mechanistic connection between AECOPD and thromboembolic disease is not clear at this time, and there is no established causal link between PE and AECOPD. Clinicians should maintain a high level of suspicion for thromboembolic disease when caring for patients with AECOPD given the known association and implications for management, specifically the need for anticoagulation.

### Indications for NIPPV

| Respiratory acidosis | pH < 7.35 with elevated PCO₂ |
|---------------------|-----------------------------|
| Respiratory distress | Noted accessory muscle use or signs of muscle fatigue |
| Severe dyspnea       | Subjective report or validated scale (NRS, VAS) |

### Absolute contraindications for NIPPV

- Patient is unable to tolerate
- Respiratory or cardiac arrest
- Diminished level of consciousness not explained by hypercapnia
- Inability to handle respiratory secretions
- High risk for aspiration (e.g., SBO)
- Facial deformity preventing adequate seal

**References**

1. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–96.
2. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204.
3. Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37(3):508–15.
4. Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007.
5. Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;346(13):988–94.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients...
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22.
7. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease. 2018;2018 Report.
8. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50:1—12.1602265 https://doi.org/10.1183/13993003.02265-2016.
9. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462.
10. Brochard L, Mancebo J, Wysocki M, Ofsthof F, Conti G, Rauss A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817–22.
11. Lightowler JV, Wedzicha JA, Elliott MW, Ram FSF. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ. 2003;326(7382):185.
12. Navales P, Fanfulla F, Frigerio P, Gregoretti C, Nava S. Physiologic evaluation of noninvasive mechanical ventilation delivered with three types of masks in patients with chronic hypercapnic respiratory failure. Crit Care Med. 2000;28(6):1785–90.
13. Girault C, Briel A, Benichou J, Hellot MF, Dachraoui F, Tamion F, et al. Interface strategy during noninvasive positive pressure ventilation for hypercapnic acute respiratory failure. Crit Care Med. 2009;37(1):124–31.
14. Nava S, Navales P, Gregoretti C. Interfaces and humidification for noninvasive mechanical ventilation. Respir Care. 2009;54(1):71–84.
15. Anton A, Guell R, Gomez J, Serrano J, Castellano A, Carrasco JL, et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic airflow limitation. Chest. 2000;117(3):828–33.
16. Conti G, Antonelli M, Navales P, Rocco M, Buò M, Spadetta G, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med. 2002;28(12):1701–7.
17. Confalonieri M, Garuti G, Cattaruzza MS, Osborn JF, Antonelli M, Conti G, et al. A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation. Eur Respir J. 2005;25(2):348–53.
18. Stefan MS, Nathanson BH, Higgins TL, Steingrub JS, Lagu T, Rothberg MB, et al. Comparative effectiveness of noninvasive and invasive ventilation in critically ill patients with acute exacerbation of chronic obstructive pulmonary disease. Crit Care Med. 2015;43(7):1386–94.
19. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016;(8):CD011826.
20. Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulised albuterol in acute exacerbations of COPD. Chest. 2005;128(1):48–54.
21. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 1995;25(4):470–3.
22. O’Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet (London, England). 1989;1(8652):1418–20.
23. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941–7.
24. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348(26):2618–25.
25. Walters JAE, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;1.
26. de Jong YP, Uil SM, Grotjohann HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007;132(6):1741–7.
27. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359–67.
28. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–31.
29. Bonilla Arcos D, Krishnan JA, Vandivier RW, Sevrsnak JE, Checkley W, Kiser TH, et al. High-dose versus low-dose systemic steroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease: systematic review. Chronic Obstr Pulm Dis. 2016;3(2):580–8.
30. Woods IA, Wheeler JS, Finch CK, Pinner NA. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:421–30.
31. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.
32. Miravilles M, Kruesmann F, Haverstock D, Perroncel R, Choudhi SH, Arvis P. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J. 2012;39(6):1354–60.
33. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–45.
34. Clark TW, Medina MJ, Batish M, Curran MD, Parmar S, Nicholson KG. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015;45(1):76–86.
35. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9–19.
36. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–49.
37. Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62(3):442–50.
38. van Eerd EA, van der Meer RM, van Schayck OC, Kolz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;(8):CD010744.
39. Morelli A, Del Sorbo L, Pesenti A, Ranieri VM, Fan E. Extracorporeal carbon dioxide removal (ECCO2R) in patients with acute respiratory failure. Intensive Care Med. 2017;43(4):519–30.
40. Pettenuzzo T, Fan E, Del Sorbo L. Extracorporeal carbon dioxide removal in acute exacerbations of chronic obstructive pulmonary disease. Ann Transl Med. 2018;6(2):31.
41. Kluge S, Braune SA, Engel M, Nierhaus A, Frings D, Ebelt H, et al. Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med. 2012;38(10):1632–9.

42. Abrams DC, Brenner K, Burkart KM, Agerstrand CL, Thomashow BM, Bacchetta M, et al. Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(4):307–14.

43. Burki NK, Mani RK, Herth FJJ, Schmidt W, Teschler H, Bonin F, et al. A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD. Chest. 2013;143(3):678–86.

44. Braune S, Sieweke A, Brettner F, Staudinger T, Joannidis M, Verbrugge S, et al. The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to noninvasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study. Intensive Care Med. 2016;42(9):1437–44.

45. Cummins C, Bentley A, McAuley DF, McNamee JJ, Patrick H, Barrett NA. A United Kingdom register study of in-hospital outcomes of patients receiving extracorporeal carbon dioxide removal. J Intensive Care Soc. 2018;19(2):114–21.

46. Sklar MC, Beloncle F, Katsios CM, Brochard L, Friedrich JO. Extracorporeal carbon dioxide removal in patients with chronic obstructive pulmonary disease: a systematic review. Intensive Care Med. 2015;41(10):1752–62.

47. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and meta-analysis. Chest. 2009;135(3):786–93.

48. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006;144(6):390–6.

49. Aleva FE, Voets L, Simons SO, de Mast Q, van der Ven A, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. Chest. 2017;151(3):544–54.